Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

0.3108 +0.0043 (+1.40%)
Streaming Delayed Price Updated: 3:11 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about FibroGen, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Analyzing FibroGen's Unusual Options Activity
Shares of FibroGen (NASDAQ:FGEN) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $13.83. Sentiment: BEARISH Option... 
Via Benzinga
FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall
FibroGen (FGEN) stock is falling hard on Friday after the company received the results of an FDA review for one of its drugs. 
Via InvestorPlace
Exposures Product Safety
Mid-Morning Market Update: Markets Down; Kansas City Southern Earnings Miss Views
Following the market opening Friday, the Dow traded down 0.41% to 34,844.89 while the NASDAQ fell 0.30% to 14,499.54. The S&P also fell, dropping 0.30% to 4,346.93. The U.S.... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Why FibroGen's Stock Is Getting Hammered Today
FibroGen, Inc. (NASDAQ: FGEN) shares are trading lower after an FDA Advisory Committee panel voted against approval of the company's New Drug Application for roxadustat to... 
Via Benzinga
Exposures Product Safety
FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment
A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday. 
Via Investor's Business Daily
Exposures Product Safety
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE: 
Via Benzinga
GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies
GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral... 
Via Benzinga
10 Biggest Price Target Changes For Friday
Credit Suisse raised Cintas Corporation (NASDAQ: CTAS) price target from $350 to $375. Cintas shares rose 1.4% to $374.12 in pre-market trading. Barclays raised the price target... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton... 
Via Benzinga
22 Stocks Moving in Friday's Pre-Market Session
Gainers Aehr Test Systems (NASDAQ: AEHR) shares rose 25.3% to $3.52 in pre-market trading after the company reported better-than-expected Q4 results and issued strong FY22 sales... 
Via Benzinga
FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?
FibroGen, Inc.’s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen’s AdCom Snub FibroGen said late Thursday the... 
Via Benzinga
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
FibroGen, Inc. (NASDAQ:FGEN) has a key catalyst Thursday w... 
Via Benzinga
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions
Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19
FibroGen In-Licenses Three HiFiBiO Programs For Cancer, Autoimmune Settings
FibroGen Inc (NASDAQ: FGEN) and HiFiBiO Therapeutics have entered into a licensing agreement for three programs in the immuno-oncology and autoimmune space.... 
Via Benzinga
FibroGen Inc (FGEN) Q1 2021 Earnings Call Transcript
FGEN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
3 Biotech Stocks Ripe for Spring Portfolio Cleaning
All down 45% or more from their 52-week highs, should you consider cutting your losses? 
Via The Motley Fool
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 13 companies achieved new lows for the year. Intriguing Points: The largest company by market cap to set a new 52-week low was Cia Paranaense De... 
Via Benzinga
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... 
Via Benzinga
Stock Market Rally Gains Steam As Apple, Microsoft, Google, Facebook Lead Tech Revival: Weekly Review
The Nasdaq fully joined the market rally, as Microsoft, Google and Facebook broke out while Apple and other growth stocks rebounded. The S&P 500 hit ahigh. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Lows On Thursday
On Thursday morning, 6 companies achieved new lows for the year. Areas of Significance: Viatris (NASDAQ:VTRS) was the largest, in terms of market cap, to set a new... 
Via Benzinga
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
36 Biggest Movers From Yesterday
Gainers UTime Limited (NASDAQ: UTME) shares jumped 110.7% to close at $82.17 on Wednesday. UTime shares jumped 875% on Tuesday after the company priced its IPO at $4 per share.... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.